Something went wrong with the connection!

Degenerative Disc Disease Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2022-2032), Evaluates DelveInsight

 Breaking News
  • No posts were found

Degenerative Disc Disease Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2022-2032), Evaluates DelveInsight

December 08
13:52 2022
Degenerative Disc Disease Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2022-2032), Evaluates DelveInsight
Delveinsight Business Research LLP
The Degenerative Disk Disease (DDD) therapeutics market dynamics is anticipated to evolve in the coming years owing to the increasing incident pool, rising funding for research and development activities, and expected entries of emerging therapies. Moreover, the advances in understanding cell biology will contribute immensely to the development of novel therapeutics for degenerative disk disease.

Globally, several key players are involved in developing drugs for DDD and associated conditions. The companies making drugs in the pipeline mostly focused on minimally invasive regenerative medicine with advanced technologies to gain substantial treatment modalities by focusing on disc regeneration.

DelveInsight’s “Degenerative Disc Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Degenerative Disc Disease market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Degenerative Disc Disease market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Degenerative Disc Disease Market

Degenerative Disc Disease: An Overview

Degenerative Disk Disease (DDD- osteochondrosis intervertebralis) is a common disorder that is characterized by progressive degeneration of the intervertebral disc, rendering them deformed and mechanically dysfunctional. It is a catchall phrase for a number of structural changes in the spine, such as loss of disc height, disc bulges, hydration, and impingement of nerves in the spine, among others.

Disc degeneration is a multifactorial occurrence with a strong genetic component, although the exact cause is unknown. Age and environmental factors contribute to the degenerative process. During the aging process during which, the intervertebral discs dehydrate, lose elasticity, and collapse.

Chronic low back pain (CLBP) affects approximately 10-15% of the adult population, equivalent to more than 30 million people in the United States and almost 40 million people across the EU5. Also, according to the research study by Michael et al. (2011) and Bao-Gan Peng (2013), approximately 7 million patients in the United States and EU-5 are thought to suffer from CLBP caused by degenerative disc disease. 

Degenerative Disc Disease (DDD) Market Drivers – 

  • Rich emerging pipeline

  • Increasing Incidence of Degenerative Disc Disease (DDD)

  • Increasing cause of low back pains & neck pain in adults 

  • Increasing geriatric population

Degenerative Disc Disease Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Degenerative Disc Disease market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Degenerative Disc Disease market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Degenerative Disc Disease Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

The Report Covers the Degenerative Disc Disease (DDD) Epidemiology Segmented by –

  • Total Prevalent Cases of Degenerative Disk Disease

  • Total Prevalent Cases of Chronic low back pain

  • Diagnosed Cases of Degenerative Disk Disease

  • Treated Cases of Degenerative Disk Disease

  • Age-specific Cases and Gender-specific Cases of Degenerative Disk Disease

  • Severity-specific Cases of Degenerative Disk Disease

Degenerative Disc Disease Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Degenerative Disc Disease market or expected to be launched during the study period. The analysis covers the Degenerative Disc Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Degenerative Disc Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How Degenerative Disc Disease Market Will Evolve by 2032 @

Degenerative Disc Disease Therapeutics Analysis

Degenerative Disc Disease can often be managed conservatively through physical therapy, chiropractic manipulative therapy, osteopathic manipulation, anti-inflammatory medications, such as non-steroidal anti-inflammatory drugs (NSAIDs), and spinal injections, epidural steroid injections that can provide pain relief. If these more moderate approaches fail to alleviate symptoms, surgery may be necessary

The pipeline for degenerative disk disease brings a positive ray of hope for potential treatment options in the market in the upcoming years. The current scenario also anticipates a positive shift in the market size owing to the launch of emerging therapies.

The Leading Companies in the Degenerative Disc Disease (DDD) Therapeutics Market Include:

  • AnGes

  • DiscGenics

  • Kuros Biosciences

  • Mesoblast

  • Ankasa Therapeutics 

  • Biorestorative Therapies

  • Mesoblast/Gruenthal

  • Affibody

  • Celgene Corporation

  • UCB

  • Vivex Biomedical, Inc.

  • Lynk Pharmaceuticals

  • Huabo Biopharm

  • Amgen

  • Izana Bioscience

  • Takeda

  • Merck Serono

  • MoonLake Immunotherapeutics

And many others

Degenerative Disc Disease (DDD) Therapies covered in the report include:

  • IDCT

  • Fibrin-PTH (KUR-113)

  • ART352-L

  • BRTX-100

  • AMG0103

  • Rexlemestrocel

  • Izokibep

  • CC 99677

  • Bimekizumab

And many more

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Degenerative Disc Disease Competitive Intelligence Analysis

4. Degenerative Disc Disease Market Overview at a Glance

5. Degenerative Disc Disease Disease Background and Overview

6. Degenerative Disc Disease Patient Journey

7. Degenerative Disc Disease Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Degenerative Disc Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Degenerative Disc Disease Unmet Needs

10. Key Endpoints of Degenerative Disc Disease Treatment

11. Degenerative Disc Disease Marketed Products

12. Degenerative Disc Disease Emerging Drugs and Latest Therapeutic Advances

13. Degenerative Disc Disease Seven Major Market Analysis

14. Attribute Analysis

15. Degenerative Disc Disease Market Outlook (In US, EU5, and Japan)

16. Degenerative Disc Disease Access and Reimbursement Overview

17. KOL Views on the Degenerative Disc Disease Market

18. Degenerative Disc Disease Market Drivers

19. Degenerative Disc Disease Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @

Other Trending Healthcare Reports By DelveInsight

Degenerative Disc Disease Pipeline Insights

The “Degenerative Disc Disease- Pipeline Insight, 2022” report provides comprehensive insights about 30+ companies and 30+ drugs in the Degenerative Disc Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. Some of the key companies in the Degenerative Disc Disease therapeutics market include AnGes, DiscGenics, Kuros Biosciences, Mesoblast, Ankasa Therapeutics, Biorestorative Therapies, Mesoblast, Celgene, UCB, Vivex, Lynk Pharmaceuticals, Huabo Biopharma, and others.

About DelveInsight
elveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Related Articles